Retatrutide 15mg

A single peptide that activates three hormone receptors at once — GIP, GLP-1 and glucagon. The GLP-1 and GIP actions suppress appetite and improve insulin response as in semaglutide and tirzepatide; the glucagon action adds something neither has, raising energy expenditure and driving fat out of the liver. In Phase 2 trials it produced up to about 24% weight loss at 48 weeks, the largest of any obesity compound reported at that stage, along with dramatic reductions in liver fat. It is in Phase 3 trials for obesity and related conditions. Available in vials from 5mg to 100mg and as a 10ml pre-filled pen.